ImmunityBio
Update in progressIBRX (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
ImmunityBio, Inc. is a San Diego-based biotechnology company developing next‑generation immunotherapies that aim to harness and sustain the patient’s immune response against cancer and infectious diseases. Its platforms cover biologics, including cytokine fusion proteins, DNA/vaccine vectors, and cell therapies, with first‑in‑human agents planned for liquid and solid tumors. Lead candidate Anktiva is used with BCG for BCG‑unresponsive bladder cancer; 3M‑052 is a synthetic TLR7/8 agonist. The company collaborates with NCI, Serum Institute, and BeOne; licenses with 3M IPC and Access to Advanced Health Institute.
Company score
- Sentiment
- 0.56
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.45
- Governance
- 0.06
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.15
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.35
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEOMr. Richard Gerald Adcock
- Employees684
- Websiteimmunitybio.com
Identifiers
- ISINUS45256X1037
- FIGIBBG007T9DYW9
- LEI529900J9XLBR4HFL4B83
- CUSIP45256X103
- CIK0001326110